Shift from Darbepoetin-α to Continuous Erythropoietin Receptor Activator Decreases Serum Aluminium Concentration in Patients on Hemodialysis

Highlights • Shifting DPO 20 μg weekly to CERA 100 μg monthly in patients on HD increases RBC number and size. • Patients with higher parathyroid hormone or lower cholesterol respond better after the shift. • This is the first report indicating CERA decreases Al and hence improves the inflammation s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Environmental toxicology and pharmacology 2016-07, Vol.45, p.108-114
Hauptverfasser:	Liu, Wen-Sheng, Chan, Hsiang-Lin, Lai, Yen-Ting, Yang, Ya-Hsu, Teng, Hao-Wei, Liu, Chih-Kuang, Li, Szu-Yuan, Yang, Chih-Yu, Liu, Tsung-Yun, Lin, Chih-Ching
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Aluminium Aluminum - blood Cholesterol - blood Continuous erythropoietin receptor activator Creatinine - blood Darbepoetin alfa - pharmacology Darbepoetin alfa - therapeutic use Emergency Erythrocyte Count Erythropoietin - pharmacology Erythropoietin - therapeutic use Erythropoietin stimulating agent Female Hematinics - pharmacology Hematinics - therapeutic use Hemodialysis Humans Male Middle Aged Parathyroid hormone Parathyroid Hormone - blood Platelet Count Polyethylene Glycols - pharmacology Polyethylene Glycols - therapeutic use Renal Dialysis Uremia - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Shifting DPO 20 μg weekly to CERA 100 μg monthly in patients on HD increases RBC number and size. • Patients with higher parathyroid hormone or lower cholesterol respond better after the shift. • This is the first report indicating CERA decreases Al and hence improves the inflammation status.
ISSN:	1382-6689 1872-7077
DOI:	10.1016/j.etap.2016.05.021